Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
CLINICAL PHARMACOLOGY / RESEARCH LETTER
A retrospective study on the effect of statins on mortality and antimicrobial resistance among patients with Staphylococcus aureus bloodstream infection
1
Department of Clinical Pharmacy, Dongguan Tungwah Hospital, Dongguan, Guangdong, China
2
Department of Pharmacy, Chang’an Hospital of Dongguan, Dongguan, Guangdong, China
Submission date: 2024-02-25
Final revision date: 2024-02-29
Acceptance date: 2024-03-09
Online publication date: 2024-03-30
Corresponding author
Arch Med Sci 2024;20(2):675-678
KEYWORDS
methicillin-resistant Staphylococcus aureusbloodstream infectionstatinsmortality ratesantibiotic resistance
TOPICS
ABSTRACT
Introduction:
There is insufficient evidence in statin on the treatment of Staphylococcus aureus (SA) infection, we observe and analyze the clinical outcomes and antibiotic resistance of SA bloodstream infections in patients who received statins.
Material and methods:
A retrospective study was carried out in SA bloodstream infection of hospitalized patients from January 2018 to August 2023. The 30-day attributable mortality, 30-day all-cause mortality and clinical data of patients who received statins and non-statins were compared.
Results:
A total of 74 patients with SA bloodstream infection were included, 32 (43.2%) patients received treatment with statins and 42 (56.8%) with non-statins. The incidence of methicillin-resistant SA (MRSA) was significantly lower in the statins group (15.6% vs. 38.1%, p = 0.034), however, no significant differences were observed in the mortality rate (p = 0.410).
Conclusions:
This study revealed the superiority of statins in reducing incidence of MRSA among SA bloodstream infection patients, but statins do not improve the 30-day mortality rate.
There is insufficient evidence in statin on the treatment of Staphylococcus aureus (SA) infection, we observe and analyze the clinical outcomes and antibiotic resistance of SA bloodstream infections in patients who received statins.
Material and methods:
A retrospective study was carried out in SA bloodstream infection of hospitalized patients from January 2018 to August 2023. The 30-day attributable mortality, 30-day all-cause mortality and clinical data of patients who received statins and non-statins were compared.
Results:
A total of 74 patients with SA bloodstream infection were included, 32 (43.2%) patients received treatment with statins and 42 (56.8%) with non-statins. The incidence of methicillin-resistant SA (MRSA) was significantly lower in the statins group (15.6% vs. 38.1%, p = 0.034), however, no significant differences were observed in the mortality rate (p = 0.410).
Conclusions:
This study revealed the superiority of statins in reducing incidence of MRSA among SA bloodstream infection patients, but statins do not improve the 30-day mortality rate.
REFERENCES (18)
1.
Jenkins TC, Price CS, Sabel AL, et al. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 1000-8.
2.
Van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 2012; 25: 362-86.
3.
Gajdács M. The continuing threat of methicillin-resistant Staphylococcus aureus. Antibiotics 2019; 8: 52.
4.
Schneider SM, Schaeg M, Gärtner BC, et al. Do written diagnosis-treatment recommendations on microbiological test reports improve the management of Staphylococcus aureus bacteremia? A single-center, retrospective, observational study. Diagn Microbiol Infect Dis 2020; 98: 115170.
5.
Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017; 120: 229-43.
6.
López-Cortés LE, Gálvez-Acebal J, Del Toro MD, et al. Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort study. PLoS One 2013; 8: e82958.
7.
Machuca J, Conejo MC, Pascual Á, et al. Potential clinical significance of statins on methicillin resistance reversion in Staphylococcus aureus. Enferm Infecc Microbiol Clin 2022; 40: 214-5.
8.
Liappis AP, Kan VL, Rochester CG, et al. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33: 1352-7.
9.
Masana L, Correig E, Rodríguez-Borjabad C, et al. Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. Eur Heart J Cardiovasc Pharmacother 2022; 8: 157-64.
10.
Yang KC, Chien JY, Tseng WK, et al. Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 2007; 25: 494-501.
11.
Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2006; 32: 160-4.
12.
Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care⁃associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
13.
Clinical and Laboratory Standards Institute. M-100 Performance standards for antimicrobial susceptibility testing[S]. Wayne PA, USA: CLSI,2015.
14.
García-Fernández E, Koch G, Wagner RM, et al. Membrane microdomain disassembly inhibits MRSA antibiotic resistance. Cell 2017; 171: 1354-67.e20.
15.
Nagendra Prasad HS, Karthik CS, Manukumar HM, et al. New approach to address antibiotic resistance: miss loading of functional membrane microdomains (FMM) of methicillin-resistant Staphylococcus aureus (MRSA). Microb Pathog 2019; 127: 106-15.
16.
Chen Y, Han L, Zheng A. Association between statin use and the risk, prognosis of gynecologic cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2022; 268: 74-81.
17.
Kim DS, Kim HJ, Ahn HS. Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean national health insurance claims database. J Cancer Res Clin Oncol 2022; 148: 2855-65.
18.
Jayalath VH, Clark R, Lajkosz K, et al. Statin use and survival among men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis. JAMA Netw Open 2022; 5: e2242676.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
